Skip to content

Blood-Bile Ratio Tacrolimus After Liver Transplantation

Use of Tacrolimus Blood-bile Ratio for the Detection of Early Liver Failure After Liver Transplantation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03882164
Acronym
BBRT
Enrollment
55
Registered
2019-03-20
Start date
2019-02-21
Completion date
2020-05-31
Last updated
2019-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunosuppression, Liver Transplant; Complications, Transplant; Complication, Rejection, Transplant Failure

Keywords

Liver transplant;, Immunosuppression;, Transplant rejection;

Brief summary

Tacrolimus is the most widely used immunosuppressive drug in the prevention of rejection after solid organ transplantation. Pharmacokinetic studies in healthy volunteers and in transplanted patients have shown that this molecule is rapidly absorbed after oral administration (maximum plasma concentration after 1-2 hours), is found in the circulation bound mainly to erythrocytes and, after being metabolized by CYP3A4, is eliminated through the bile. The importance of the tacrolimus blood dosage is now widely recognized for detecting the immunosuppressive capacity reached in the individual patient or the eventual overdose of the drug. In the use of Tacrolimus after Liver Transplantation, however, it is interesting to note that the biochemical pathway for metabolism and excretion of the drug is present in the transplanted organ, the main object of immunological and functional surveillance. The excretory capacity of Tacrolimus by the liver through the bile, therefore, could be a useful tool for recognizing the early liver failure from a functional point of view, before the onset of hepatoecrosis.

Detailed description

Prospective monocentric randomized study comparing two parallel groups: liver transplanted patients with early (10 POD) organ rejection (experimental arm); liver transplanted patients without early (10 POD) organ rejection (control arm) Primary Objective: Evaluation of a correlation between the reduction of Tacrolimus biliary excretion and the early liver failure Primary Endpoint: Increase of Tacrolimus blood-bile ratio measured before the onset of laboratory hepatonecrosis Secondary Objective: Analysis of the cause of any drug-related toxicity Secondary Endpoint: correlation study between drug dosage and biliary excretion level in case of blood overdose or clinical evidence of pharmacological toxicity

Interventions

DIAGNOSTIC_TESTBlood-Bile Ratio of Tacrolimus

Diagnosis of early transplanted liver dysfunction to adjust Tacrolimus dose adminstered

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * History of recent liver transplant (less than 10 days) * Placement of kehr tube in the biliary tract during liver transplant * Immunosuppressive therapy with Tacrolimus * Functioning of kehr tube

Exclusion criteria

* Age - Age ≥18 years * History of liver transplant for more than 10 days * Liver transplant without positioning of kehr tube * Immunosuppressive therapy with a drug different from Tacrolimus * No functioning of kehr tube18 years * History of liver transplant for more than 10 days * Liver transplant without positioning of kehr tube * Immunosuppressive therapy with a drug different from Tacrolimus * No functioning of kehr tube

Design outcomes

Primary

MeasureTime frameDescription
Analysis of early liver rejection10 daysEvaluation of early liver rejection throught creation of a Tacrolimus blood-bile ratio

Secondary

MeasureTime frameDescription
Analysis of Tacrolimus toxicity10 daysEvaluation of Tacrolimus toxicity throught blood dosage of the drug

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026